Literature DB >> 24817958

Retrospective analysis of 80 cases with uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma in China, 1988-2007.

Yuan Gao1, Hao Meng2, Yemin Zhang3, Tingting Jiao3, Ning Hui3.   

Abstract

OBJECTIVE: Uterine sarcomas are rare gynecological malignancies with poor prognosis and high mortality. We provides clinical information of uterine sarcoma patients at Changhai Hospital of Secondary Military Medical University in Shanghai, China, over a 20-year period. DESIGN AND METHODS: Satisfied the criteria for the study, a total of 80 female patients with uterine sarcomas were retrospectively evaluated. Overall survival was analyzed by Kaplan-Meier method. MAIN OUTCOME MEASURES: The following information was extracted from our medical records: age, presentations, blood types, stages, ultrasonographic results, therapies and follow-up.
RESULTS: Of the 80 patients, the mean age of onset was 57.3±2.03 years, and the highest frequency occurred in 51-60 age group. Endometrial stromal sarcoma was the most common histological type (47.5%). Even population of these patients presented was with early stage (I&II) and advanced stages (III&IV). Among 79 patients underwent primary surgery, 74 cases was hysterectomy and bilateral salping-ooophorectomy. Equal to disease-specific survival, overall survival rates at 1-, 3- and 5-year were 81.3%, 62.5% and 40% respectively. Age, menopausal status, blood type, stage, and pathologic types were all proved to be correlated with the survival.
CONCLUSION: Our retrospective data in part reflect clinical characteristics of uterine sarcoma in China, and form the basis for further concerning researches.

Entities:  

Keywords:  Carcinosarcoma; China; blood type; endometrial stromal sarcoma; leiomyosarcoma; prognosis

Mesh:

Year:  2014        PMID: 24817958      PMCID: PMC4014242     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  30 in total

Review 1.  Association of tamoxifen and uterine sarcoma.

Authors:  D Lawrence Wickerham; Bernard Fisher; Norman Wolmark; John Bryant; Joseph Costantino; Leslie Bernstein; Carolyn D Runowicz
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

Review 2.  Prognostic factors in uterine sarcoma.

Authors:  Angiolo Gadducci
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2011-07-18       Impact factor: 5.237

3.  Management of intravenous leiomyomatosis with intracaval and intracardiac extension.

Authors:  Jinhui Wang; Jiaxin Yang; Huifang Huang; Yuan Li; Qi Miao; Xin Lu; Yongjun Li; Ning Yang; Yuguang Huang; Jie Chen; Dongyan Cao; Ming Wu; Lingya Pan; Jinghe Lang; Keng Shen
Journal:  Obstet Gynecol       Date:  2012-12       Impact factor: 7.661

4.  [WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics].

Authors:  W Böcker
Journal:  Verh Dtsch Ges Pathol       Date:  2002

5.  ABO and Rh blood groups in relation to ovarian, endometrial and cervical cancer risk among the population of South-East Siberia.

Authors:  Arseniy E Yuzhalin; Anton G Kutikhin
Journal:  Asian Pac J Cancer Prev       Date:  2012

6.  The clinical and histologic spectrum of endometrial stromal neoplasms: a report of 41 cases.

Authors:  P S Fekete; F Vellios
Journal:  Int J Gynecol Pathol       Date:  1984       Impact factor: 2.762

7.  Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus.

Authors:  Mario M Leitao; Yukio Sonoda; Murray F Brennan; Richard R Barakat; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2003-10       Impact factor: 5.482

8.  Comment on: Risk of pancreatic cancer in relation to ABO blood group and hepatitis C virus infection in Korea: a case-control study.

Authors:  Ali Kabir
Journal:  J Korean Med Sci       Date:  2013-07       Impact factor: 2.153

9.  Prognostic factors and treatment outcomes in 93 patients with uterine sarcoma from 4 centers in Turkey.

Authors:  Ayşe Durnali; Saadet Tokluoğlu; Nuriye Özdemir; Mevlüde Inanç; Necati Alkiş; Nurullah Zengin; Özlem Uysal Sönmez; Mehmet Küçüköner
Journal:  Asian Pac J Cancer Prev       Date:  2012

10.  Risk of pancreatic cancer in relation to ABO blood group and hepatitis C virus infection in Korea: a case-control study.

Authors:  Sang Myung Woo; Jungnam Joo; Woo Jin Lee; Sang-Jae Park; Sung-Sik Han; Tae Hyun Kim; Young Hwan Koh; Hyun Bum Kim; Eun Kyung Hong
Journal:  J Korean Med Sci       Date:  2013-01-29       Impact factor: 2.153

View more
  5 in total

1.  Uterine Sarcoma: Retrospective Study From A Single institute.

Authors:  S Suchetha; T Vijayashanti; P Rema; J Sivaranjith; Aswin Kumar; K M Jagathnath Krishna; Francis V James
Journal:  J Obstet Gynaecol India       Date:  2022-02-23

2.  Unexpected uterine sarcomas after hysterectomy and myomectomy for presumed leiomyoma: a retrospective study of 26,643 patients.

Authors:  Hanyu Cao; Lin Li; Mingrong Xi; Bowen Yang; Gupo Luo; Jiangyan Lou
Journal:  Cancer Manag Res       Date:  2019-07-25       Impact factor: 3.989

3.  A Real-World Study on Diagnosis and Treatment of Uterine Sarcoma in Western China.

Authors:  Dan Li; Na Yin; Guobo Du; Shaohua Wang; Zhibo Xiao; Jinyun Chen; Wenzhi Chen
Journal:  Int J Biol Sci       Date:  2020-01-01       Impact factor: 6.580

4.  Retrospective Analysis of Patients with Gynaecological Uterine Sarcomas in a Tertiary Hospital.

Authors:  Maria Ruiz-Minaya; Elsa Mendizabal-Vicente; Wenceslao Vasquez-Jimenez; Laura Perez-Burrel; Irene Aracil-Moreno; Carolina Agra-Pujol; Mireia Bernal-Claverol; Beatriz L Martínez-Bernal; Mercedes Muñoz-Fernández; Melanie Morote-Gonzalez; Miguel A Ortega; Santiago Lizarraga-Bonelli; Juan A De Leon-Luis
Journal:  J Pers Med       Date:  2022-02-06

5.  The value of clinical parameters combined with magnetic resonance imaging (MRI) features for preoperatively distinguishing different subtypes of uterine sarcomas: An observational study (STROBE compliant).

Authors:  Qiu Bi; Kunhua Wu; Fajin Lv; Zhibo Xiao; Yulin Xiong; Yiqing Shen
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.